ACVR2B and Duchenne muscular dystrophy: A study demonstrated that the combined inhibition of ActRIIb and exon skipping for dystrophin using an adeno-associated vector enhanced the tetanic and specific forces in the mdx mouse model for Duchenne muscular dystrophy, indicating a potential therapeutic strategy for muscle wasting diseases [30].